Janux Therapeutics, Inc. (NASDAQ: JANX)

Janux Therapeutics, Inc. is an innovative clinical stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform creates T cell engagers that link a tumor antigen binding domain to a CD3 binding domain, while the TRACIr platform pairs a tumor antigen binding domain with a costimulatory CD28 binding domain. The ARM platform redesigns bispecific T cell engagers to achieve controlled T cell activation, expansion, and contraction for durable B cell depletion in autoimmune disease. The lead clinical candidate, JANX007, is a PSMA directed TRACTr in Phase 1 trials for metastatic castration resistant prostate cancer, showing prostate specific antigen reductions and a manageable safety profile with cytokine release syndrome mainly confined to the first treatment cycle. A second candidate, JANX008, is an EGFR directed TRACTr under investigation in multiple solid tumor types, demonstrating early anti tumor activity and low grade cytokine release in Phase 1 testing. Janux is also advancing JANX011, a CD19 targeted ARM program, in a Phase 1 study of healthy volunteers to assess safety, tolerability, pharmacokinetics, and pharmacodynamics for potential autoimmune indications. Additional TRACTr, TRACIr, and ARM molecules targeting various tumor and immune antigens are being generated using the modular nature of the platforms.

Janux Therapeutics generates revenue primarily from upfront payments, milestone payments, and potential royalties under its collaboration and license agreements with Merck Sharp & Dohme Corp. and Bristol Myers Squibb. The Merck agreement, signed in December 2020, provided an $8.0 million upfront payment for each of two selected targets, with potential development and regulatory milestones up to $142.5 million per target ($285 million total) and up to $350 million in sales based milestones per target, plus tiered royalties ranging from low single digit to low teen percentages on net sales. The Bristol Myers Squibb agreement, executed in January 2026, granted a $15.0 million upfront payment and the opportunity to earn up to $785 million in milestone payments, including a near term $35 million milestone, along with tiered royalties from high single digit to low double digit percentages on global net sales. To date, the company has not recorded any product sales revenue.

Janux Therapeutics competes with large pharmaceutical and biotechnology firms such as AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Merck & Co., Gilead, GSK, Johnson & Johnson, Lilly, Novartis, Pfizer, Regeneron, Sanofi, and Roche/Genentech, many of which pursue T cell engagers, antibody drug conjugates, CAR T cell therapies, and other immunomodulators for oncology and autoimmune diseases. Direct rivals for its PSMA targeted program include antibody drug conjugates from AbbVie, AstraZeneca, and Novartis, CAR T cell therapies from Gilead, and radiopharmaceuticals from AstraZeneca, BMS, Johnson & Johnson, Novartis, Lantheus/Lilly, Telix, and Bayer. Competitors for its EGFR targeted program consist of approved agents such as Genmab/Janssen’s amivantamab, Roche’s bevacizumab, Amgen’s panitumumab, Eli Lilly/Merck KGaA’s cetuximab, Bayer’s regorafenib, and Eli Lilly’s ramucirumab, as well as emerging candidates from AstraZeneca, Bristol Myers Squibb, Dragonfly, KangaBio, Lava Therapeutics/Pfizer, Merus, Regeneron, Chugai/Roche, and Vir Biotechnology. The company’s advantages stem from its proprietary TRACTr and TRACIr platforms, which employ tumor activated peptide masks to limit activity to the tumor microenvironment, incorporate an albumin binding domain to extend half life before activation, retain efficacy at low antigen expression, and enable rapid generation of new candidates through a modular design that resembles monoclonal antibody manufacturing.

Although Janux Therapeutics has not yet commercialized a product, its collaborations with Merck and Bristol Myers Squibb constitute its current customer base for partnered programs. The pipeline aims to treat patients with solid tumors such as metastatic castration resistant prostate cancer (via JANX007) and various EGFR expressing cancers (via JANX008), as well as individuals with autoimmune diseases who may benefit from B cell depleting therapies like JANX011. Expected end users are oncologists, urologists, immunologists, and other healthcare specialists, together with hospitals, infusion centers, and managed care organizations that will administer and pay for the therapies. Payers and reimbursement entities are also anticipated to become important customers once the products demonstrate sufficient clinical efficacy and safety to secure coverage and favorable reimbursement policies.